AstraZeneca PLC (OTCMKTS:AZNCF) Short Interest Up 248.8% in November

AstraZeneca PLC (OTCMKTS:AZNCF) saw a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 147,200 shares, an increase of 248.8% from the October 31st total of 42,200 shares. Based on an average daily volume of 3,800 shares, the days-to-cover ratio is presently 38.7 days.

Hedge Funds Weigh In On AstraZeneca

A hedge fund recently bought a new stake in AstraZeneca stock. Eagle Bay Advisors LLC acquired a new position in AstraZeneca PLC (OTCMKTS:AZNCF) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,001 shares of the company’s stock, valued at approximately $156,000. 40.87% of the stock is owned by institutional investors.

AstraZeneca Stock Performance

OTCMKTS AZNCF traded up $3.34 on Thursday, hitting $134.70. The stock had a trading volume of 791 shares, compared to its average volume of 2,655. The firm has a 50-day moving average of $143.89 and a 200-day moving average of $154.12. AstraZeneca has a 52-week low of $118.16 and a 52-week high of $175.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.